PA
OVID icon

Profund Advisors’s Ovid Therapeutics OVID Stock Holding History

Profund Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187K Buy
+69,699
New +$180K 0.01% 1104

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Profund Advisors's OVID Position: Q2 2026 in Review

Profund Advisors opened a new position in Ovid Therapeutics (OVID) in Q2 2026: 69,699 shares worth $187K. The stake represents 0.01% of the portfolio and ranks #1104 among its holdings.

131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Profund Advisors held 69,699 shares of Ovid Therapeutics worth $187K as of Q2 2026.
  • Ovid Therapeutics was a new Profund Advisors position in Q2 2026.
  • Ovid Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #1104 holding.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.